Ocuphire Pharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Opus Genetics, Inc. (Nasdaq: IRD), formerly Ocuphire Pharma, Inc., operates as a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for inherited retinal diseases and other retinal and refractive eye disorders. The company advances adeno-associated virus-based gene therapies targeting mutations causing bestrophinopathy, Leber congenital amaurosis including LCA5, and retinitis pigmentosa; its lead candidate OPGx-LCA5, with Rare Pediatric Disease and Orphan Drug Designations from the FDA, demonstrates visual improvements in Phase 1/2 trials for early-onset retinal degeneration. Additional pipeline assets include Phentolamine Ophthalmic Solution 0.75% (RYZUMVI), approved for reversal of pharmacologically induced mydriasis and under evaluation in Phase 3 LYNX-2 and VEGA-3 trials for dim light disturbances post-keratorefractive surgery and presbyopia, respectively; and APX3330, an oral Ref-1 inhibitor for non-proliferative diabetic retinopathy, for which the company seeks a strategic partner. Founded in 2018 and headquartered in Farmington Hills, Michigan, the company primarily serves patients with unmet needs in ocular therapeutics through U.S.-based operations and global development collaborations. In October 2024, Ocuphire completed an all-stock acquisition of Opus Genetics, Inc., renaming the combined entity Opus Genetics effective October 23, 2024, with the ticker changing to IRD on October 24, 2024; pre-acquisition Ocuphire shareholders retain approximately 58% ownership. The transaction integrates Opus's gene therapy portfolio, extends cash runway into 2026, and adds expertise via new board members including Jean Bennett, Ben Yerxa, and Adrienne Graves; upcoming milestones encompass pediatric OPGx-LCA5 data, initial OPGx-BEST1 results, and top-line readouts from LYNX-2 in Q1 2025 and VEGA-3 in H1 2025.
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
Ocuphire Pharma Announces Acquisition of Opus Genetics
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
Ocuphire Pharma to Present at Two Investor Conferences in August
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)